Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients

Journal of Thoracic Oncology

Volumn 5, Issue 9, 2010, Pages 1325-1336

  Sterlacci, William ^a   Fiegl, Michael ^b   Hilbe, Wolfgang ^b   Jamnig, Herbert ^c   Oberaigner, Wilhelm ^d   Schmid, Thomas ^a   Augustin, Florian ^a   Auberger, Jutta ^e   Obermann, Ellen C ^f   Tzankov, Alexandar ^f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Natters Hospital   (Austria)

^d Institute for Clinical Epidemiology   (Austria)

^e St Johanns Spital   (Austria)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cyclin D1; EGFR; Epithelial mesenchymal transition; Non small cell lung cancer; p27

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; CELL CYCLE G1 PHASE; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MITOSIS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SURVIVAL TIME; TISSUE MICROARRAY;

EID: 77956267400     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e77efc     Document Type: Article

References (45)

1. Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regula-tion of TWIST gene expression. Cancer Res 2007;67:9066-9076.
2. Lu Z, Ghosh S, Wang Z, et al. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4: 499-515.
3. Cano A, Pérez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cad-herin expression. Nat Cell Biol 2000;2:76-83.
4. Lee MY, Chou CY, Tang MJ, et al. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res 2008;14:4743-4750.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354; erratum 580.
6. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19:2474-2488.
7. Meier C, Hoeller S, Bourgau C, et al. Recurrent numeric aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009;22:476-487.
8. Yu H, Jove R. The STATs of cancer\new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
9. Kusaba T, Nakayama T, Yamazumi K, et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 2006;15:1445-1451.
10. Engelman JA. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res 2007;13:4637-4640.
11. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
12. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-6871.
13. Travis W, Brambilla E, Müller-Hermelink H, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
14. Sterlacci W, Fiegl M, Hilbe W, et al. Clinical relevance of neuroendo-crine differentiation in non-small cell lung cancer assessed by immuno-histochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 2009;455:125-132.
15. Fiegl M, Hilbe W, Auberger J, et al. Twelve-year retrospective analysis of lung cancer-the TYROL Study: daily routine in 1,424 patients (1995-2006). J Clin Oncol 2008;20:19063.
16. Hilbe W, Aigner K, Dittrich C, et al. Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms. Wien Klin Wochenschr 2007;119:259-266.
17. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
18. Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010; 51:199-212.
19. Yoo J, Jung JH, Lee MA, et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007;22:318-325.
20. Tzankov A, Went P, Zimpfer A, et al. Tissue microarray technology: principles, pitfalls and perspectives\lessons learned from hematologi-cal malignancies. Exp Gerontol 2005;40:737-744.
21. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
22. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234.
23. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230.
24. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323.
25. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005;11:3974-3986.
26. Qi CF, Xiang S, Shin MS, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res 2006;30:153-163.
27. Sánchez-Beato M, Camacho FI, Martínez-Montero JC, et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocal-ization in tumor cells. Blood 1999;94:765-772.
28. Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adeno-carcinomas. Int J Gynecol Pathol 2003;22:378-385.
29. Volgareva G, Zavalishina L, Andreeva Y, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004;4:58.
30. Yildiz IZ, Usubütün A, Firat P, et al. Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract 2007;203:445-449.
31. Lipponen P, Saarelainen E, Ji H, et al. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 1994;174:101-109.
32. Elzagheid A, Kuopio T, Ilmen M, et al. Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance. Histopathology 2002;41:127-133.
33. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003;5:R217-R222.
34. Liu LK, Jiang XY, Zhou XX, et al. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 2010;23:213-224.
35. Lazr D, Tban S, Ardeleanu C, et al. The immunohistochemical expression of E-cadherin in gastric cancer: correlations with clinicopathological factors and patients' survival. Rom J Morphol Embryol 2008;49:459-467.
36. Xu HT, Li QC, Zhang YX, et al. Connexin 43 recruits E-cadherin expression and inhibits the malignant behaviour of lung cancer cells. Folia Histochem Cytobiol 2008;46:315-321.
37. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.
38. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
39. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
40. Gautschi O, Ratschiller D, Gugger M, et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55:1-14.
41. Marchetti A, Doglioni C, Barbareschi M, et al. Cyclin D1 and retino-blastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998;75:187-192.
42. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73:294-300.
43. Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-2983.
44. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-1817.
45. Kobayashi S, Shimamura T, Monti S, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006;66:11389-11398.